Last Posted: Aug 16, 2018
- Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.
Presley Carolyn J et al. JAMA 2018 Aug 320(5) 469-477 - Broad-Based Molecular Testing for Lung Cancer: Precisely the Time for Precision.
Bunn Paul A et al. JAMA 2018 Aug 320(5) 445-446 - Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer.
Kimura M et al. Molecular and clinical oncology 2018 Aug 9(2) 201-206 - EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand.
McKeage Mark et al. Targeted oncology 2017 12(5) 663-675 - Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment.
Tan Lavinia et al. PET clinics 2018 Jan 13(1) 33-42 - Large-Scale EGFR Mutation Testing in Clinical Practice: Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases.
Evans Matthew et al. Pathology oncology research : POR 2018 Aug - The diagnostic role of plasma circulating precursors of miRNA-944 and miRNA-3662 for non-small cell lung cancer detection.
Powrózek Tomasz et al. Pathology, research and practice 2017 Nov 213(11) 1384-1387 - Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.
Devarakonda Siddhartha et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Aug JCO2018781963 - Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting
CJ Presley et al, JAMA, August 7 2018 - Broad-Based Molecular Testing for Lung Cancer- Precisely the Time for Precision
PA Bunn et al. JAMA< AUgust 7, 2018
.png)
No hay comentarios:
Publicar un comentario